{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:29:06Z","timestamp":1780756146663,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12328-019-00938-2","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T10:27:19Z","timestamp":1548930439000},"page":"341-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt"],"prefix":"10.1007","volume":"12","author":[{"given":"Maiko","family":"Namba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Morio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Awai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"638747","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Maysui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014;2014:638747.","journal-title":"J Thyroid Res"},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"938_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/hepr13243","author":"A Hiraoka","year":"2018","unstructured":"Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res 2018. \n                    https:\/\/doi.org\/10.1111\/hepr13243\n                    \n                  .","journal-title":"Hepatol Res"},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/hepr.12181","volume":"44","author":"N Naeshiro","year":"2014","unstructured":"Naeshiro N, Kakizawa H, Aikata H, et al. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: long-term outcomes in 14 patients. Hepatol Res. 2014;44:740\u20139.","journal-title":"Hepatol Res"},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jvir.2012.05.046","volume":"23","author":"A Mukund","year":"2012","unstructured":"Mukund A, Rajesh S, Arora A, et al. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients foam sclerotherapy: initial experience. J Vasc Interv Radiol. 2012;23:1200\u20136.","journal-title":"J Vasc Interv Radiol"},{"key":"938_CR8","first-page":"1867","volume-title":"Harrison\u2019s principles of Internal Medicine","author":"RT Chung","year":"2005","unstructured":"Chung RT, Podolsky DK. Cirrhosis and its complications. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jamesoen JL, editors. Harrison\u2019s principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005. pp.\u00a01867\u20139.","edition":"16"},{"key":"938_CR9","first-page":"410","volume-title":"Hepatic cirrhosis. Disease of the liver and biliary system","author":"S Sherlock","year":"1989","unstructured":"Sherlock S. Hepatic cirrhosis. Disease of the liver and biliary system, 8th edn. London: Blackwell; 1989. p. 410\u2013424.","edition":"8"},{"issue":"2","key":"938_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1478-3231.2011.02579.x","volume":"32","author":"Y Iwakiri","year":"2012","unstructured":"Iwakiri Y. Endothelial dysfunction in the regulation of portal hypertension. Liver Int. 2012;32(2):199\u2013213.","journal-title":"Liver Int"},{"key":"938_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/hep.22089","volume":"47","author":"G Anegawa","year":"2008","unstructured":"Anegawa G, Kawanaka H, Yoshida D, et al. Defective endothelial nitric oxide synthase signalling is mediated by Rho-kinase activation in rats with secondary biliary cirrhosis. Hepatology. 2008;47:966\u201377.","journal-title":"Hepatology"},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jhep.2005.04.002","volume":"43","author":"Richard Moreau","year":"2005","unstructured":"Richard Moreau. VEGF-induced angiogenesis drives collateral circulation in portal hypertension. J Hepatol. 2005;43:6\u20138.","journal-title":"J Hepatol"},{"issue":"5","key":"938_CR13","doi-asserted-by":"publisher","first-page":"e205-11","DOI":"10.1016\/j.ejrad.2012.12.004","volume":"82","author":"E Frampas","year":"2013","unstructured":"Frampas E, Lassau N, Zappa M, et al. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results. Eur J Radiol. 2013;82(5):e205-11.","journal-title":"Eur J Radiol"},{"issue":"4","key":"938_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/liv.12098","volume":"33","author":"K Sugimoto","year":"2013","unstructured":"Sugimoto K, Moriyasu F, Saito K, et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int. 2013;33(4):605\u201315.","journal-title":"Liver Int"},{"issue":"9","key":"938_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.dld.2013.03.004","volume":"45","author":"R Sacco","year":"2013","unstructured":"Sacco R, Faggioni L, Bargellini I, et al. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. Dig Liver Dis. 2013;45(9):776\u201381.","journal-title":"Dig Liver Dis"},{"key":"938_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0002-9610(81)90294-4","volume":"142","author":"SS Hanna","year":"1981","unstructured":"Hanna SS, Smith RS III, Henderson JM, et al. Reversal of hepatic encephalopathy after occlusion of total portasystemic shunts. Am J Surg. 1981;142:285\u20139.","journal-title":"Am J Surg"},{"key":"938_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0016-5085(84)90146-X","volume":"87","author":"JR Potts","year":"1984","unstructured":"Potts JR, Henderson JM, Millikan WJ, et al. Restoration of portal venous perfusion and reversal of encephalopathy by balloon occlusion of portal systemic shunt. Gastroenterology. 1984;87:208\u201312.","journal-title":"Gastroenterology"},{"key":"938_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1148\/radiology.165.3.3685350","volume":"165","author":"R Uflacker","year":"1987","unstructured":"Uflacker R, Silva Ade O, d\u2019Albuquerque LA, et al. Chronic portosystemic encephalopathy: embolization of portosystemic shunts. Radiology. 1987;165:721\u20135.","journal-title":"Radiology"},{"key":"938_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00270-013-0715-y","volume":"37","author":"WE Saad","year":"2014","unstructured":"Saad WE, Simon PO Jr, Rose SC. Balloon-occluded retrograde transvenous obliteration of gastric varices. Cardiovasc Interv Radiol. 2014;37:299\u2013315.","journal-title":"Cardiovasc Interv Radiol"},{"key":"938_CR20","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/hep.26314","volume":"57","author":"W Laleman","year":"2013","unstructured":"Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57:2448\u201357.","journal-title":"Hepatology"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-019-00938-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00938-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-00938-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:22:19Z","timestamp":1580430139000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-019-00938-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s12328-019-00938-2","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Kazuaki Chayama has received honorarium from MSD, Bristol-Myers Squibb, AbbVie, Ajinomoto Pharma, Abbott, Astellas Pharma, Chugai, Dainippon Sumitomo Pharma, Gilead Sciences, Mitsubishi Tanabe. Kazuaki Chayama has received research funding from Janssen, Mitsubishi Tanabe, Dainippon Sumitomo, Toray. Kazuo Awai has research funding from Canon Medical Systems, Hitachi, Rrserch. Kazuaki Chayama has received educational grants from AbbVie, Dainippon Sumitomo, Ajinomoto Pharma, MSD, Eisai, Toray, Otsuka, Mitsubishi Tanabe, Chugai, Daiichi Sankyo, Takeda, Nippon Kayaku, Bristol-Myers Squibb, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}